Sensitivity and specificity of human T-lymphotropic virus (HTLV) types I and II polymerase chain reaction and several serologic assays in screening a population with a high prevalence of HTLV-II

Transfusion

Volumn 39, Issue 11-12, 1999, Pages 1185-1193

  Liu, H ^b   Shah, M ^b   Stramer, S L ^b   Chen, W ^b   Weiblen, B J ^b   Murphy, E L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOBLOTTING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RELIABILITY; SCREENING TEST; VIRUS DETECTION;

ADULT; ANTIBODIES, VIRAL; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; IMMUNOENZYME TECHNIQUES; MASS SCREENING; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREVALENCE; SENSITIVITY AND SPECIFICITY;

EID: 0032715791     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1999.39111185.x     Document Type: Article

References (25)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980;77:7415-9.
2. Manns A, Cleghorn F, Falk RT, et al. Role of HTLV-I in the development of non-Hodgkin's lymphoma in Jamaica and Trinidad and Tobago. Lancet 1993;342:1447-50.
3. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 1984;81:2534-7.
4. Gessain A, Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1992;117:933-46.
5. Kramer A, Maloney EM, Morgan OS, et al. Risk factors for human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica. Am J Epidemiol 1995;142:1212-20.
6. Gebretsadik T, Murphy EL. Counseling and medical evaluation of HTLV-I and -II-infected patients. In: Volberding P, Jacobson M, eds. AIDS clinical review. New York: Marcel Dekker, 1993:19-41.
7. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218:571-3.
8. Chen IS, McLaughlin J, Gasson JC, et al. Molecular characterization of genome of a novel human T-cell leukaemia virus. Nature 1983;305:502-5.
9. Rosenblatt JD, Danon Y, Black AC. A decade with HTLV-I/ HTLV-II: lessons in viral leukemogenesis. Leukemia 1992;6(Suppl 1):18-23.
10. Hjelle B, Appenzeller O, Mills R, et al. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992;339:645-6.
11. Murphy EL, Engstrom JW, Miller K, et al. HTLV-II-associated myelopathy in 43-year-old woman. REDS Investigators. Lancet 1993;341:757-8.
12. Murphy EL, Fridey J, Smith JW, et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS Investigators. Neurology 1997;48:315-20.
13. Modahl LE, Young KC, Varney KF, et al. Are HTLV-II-seropositive injection drug users at increased risk of bacterial pneumonia, abscess, and lymphadenopathy? J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:169-75.
14. Murphy EL, Glynn SA, Fridey J, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I-and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis 1997;176:1468-75.
15. Licensure of screening tests for antibody to human T-lymphotropic virus type I. MMWR Morb Mortal Wkly Rep 1988;37:736-40, 745-7.
16. Lillehoj EP, Alexander SS, Dubrule CJ, et al. Development and evaluation of a human T-cell leukemia virus type I serologic confirmatory assay incorporating a recombinant envelope polypeptide. J Clin Microbiol 1990;28:2653-8.
17. Roberts BD, Foung SK, Lipka JJ, et al. Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus type I and II. J Clin Microbiol 1993;31:260-4.
18. Lal RB, Heneine W, Rudolph DL, et al. Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals. J Clin Microbiol 1991;29:2253-8.
19. Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Centers for Disease Control and Prevention and the USPHS Working Group. Ann Intern Med 1993;118:448-54.
20. Ehrlich GD, Glaser JB, LaVigne K, et al. Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: type-specific identification of HTLVs by polymerase chain reaction. Blood 1989;74:1658-64.
21. Agranoff D, Varney K, Khayam-Bashi H, Murphy EL. Human T-lymphotropic virus type II seroprevalence among emergency department and clinic patients. West J Med 1996;164:481-5
22. Wiktor SZ, Pate EJ, Weiss SH, et al. Sensitivity of HTLV-I antibody assays for HTLV-II (letter). Lancet 1991;338:512-3.
23. Roberts CR, Mitra R, Hyams K, et al. Serologic differentiation of human T lymphotropic virus type I from type II infection by synthetic peptide immunoassays. J Med Virol 1992;36:298-302.
24. Mahieux R, Pecon-Slattery J, Gessain A. Molecular characterization and phylogenetic analyses of a new, highly divergent simian T-cell lymphotropic virus type 1 (STLV-lmarcl) in Macaca arctoides. J Virol 1997;71:6253-8.
25. Gallo D, Penning LM, Diggs J, Hanson CV. Sensitivities of radioimmunoprecipitation assay and PCR for detection of human T-lymphotropic type II infection. J Clin Microbiol 1994;32:2464-7.